Drug Type Fusion protein |
Synonyms anti-ROR1 TAC T-cell therapy (Triumvira Immunologics), TAC01-ROR1 |
Target |
Action modulators |
Mechanism ROR1 modulators(Inactive tyrosine-protein kinase transmembrane receptor ROR1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | United States | 26 Mar 2020 |